ARBs have "provocative" link to cancer, suggests meta-analysis
This article was originally published in Scrip
Executive Summary
Angiotensin receptor blockers (ARBs) that are widely used for the treatment of hypertension are associated with an increased risk of new cancer diagnosis, a meta-analysis published recently in The Lancet Oncology suggests.